Business Context and Reporting Period
This Form 6-K filing by Akari Therapeutics Plc is dated May 11, 2017. The report addresses a significant corporate governance and communications issue regarding a third-party research report issued by Edison Investment Research Ltd. on April 26, 2017, which the Company stated contained material inaccuracies concerning its Phase 2 PNH trial of Coversin.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and the retraction of an external analyst report rather than financial performance.
Material Changes
- Edison Report Withdrawal: Edison Investment Research Ltd. withdrew its April 26, 2017 report titled "Akari's Coversin matches Soliris in Phase II" due to material inaccuracies regarding the interim analysis of the Company's Phase 2 PNH trial.
- Management Action: Dr. Gur Roshwalb, Chief Executive Officer, has been placed on administrative leave pending a review by an ad hoc special committee of the Board of Directors regarding potential involvement of Company personnel with the Edison Report.
- Leadership Transition: Dr. Ray Prudo, Executive Chairman, is temporarily assuming the duties of the CEO during Dr. Roshwalb's absence.
Guidance, Outlook, and Risks
The Company cautions investors not to rely on the withdrawn Edison Report and directs them to the Company's press release issued on April 24, 2017, for accurate information regarding the interim analysis of the Phase 2 PNH trial. The primary risk highlighted is the potential involvement of Company personnel in the dissemination of inaccurate information, which is currently under internal review.
Key Facts for Investor Verification
- Verify the accuracy of the interim analysis of the Phase 2 PNH trial of Coversin as presented in the Company's April 24, 2017 press release.
- Monitor the outcome of the Board's ad hoc special committee review regarding the involvement of Company personnel in the Edison Report.
- Confirm the duration of Dr. Roshwalb's administrative leave and the status of Dr. Prudo's temporary assumption of CEO duties.